AMGN Earnings Date: Nov 3, 2026 (Estimated) — Amgen Inc.
NASDAQ · Healthcare · Drug Manufacturers - General
Updated
When is AMGN's next earnings date?
Amgen Inc. (AMGN) is expected to report Q3 2026 earnings on Tuesday, November 3, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $5.79 on revenue of $10.07B.
How did AMGN do in its last earnings report?
In its most recent report on Aug 4, 2026 (Q2 2026), Amgen Inc. posted EPS of $6.29 versus the $5.62 estimate, a beat of 12.3%. Revenue was $10.05B against a $9.43B estimate. The stock's 1-day post-earnings move was +4.6%.
How much does AMGN stock move after earnings?
AMGN beat EPS estimates in 8 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 4.9% (up or down) in the day after earnings.
About Amgen Inc.
Amgen Inc., established in 1980 and headquartered in Thousand Oaks, California, is a global biotechnology leader focused on discovering, developing, manufacturing, and delivering groundbreaking human medicines. The company's scientific endeavors span several critical therapeutic categories, including inflammatory conditions, oncology and hematology, bone health, cardiovascular diseases, nephrology, and neuroscience. Its extensive portfolio features a range of significant pharmaceutical products. Notable examples include Enbrel, prescribed for conditions like plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, which helps cancer patients by reducing the risk of infection linked to a low white blood cell count; Prolia, utilized in postmenopausal women to combat osteoporosis; and Xgeva, designed to prevent skeletal-related complications. Otezla offers relief for adult patients suffering from plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease. Aranesp addresses anemia and low red blood cell counts, while KYPROLIS is employed to treat patients with relapsed or refractory multiple myeloma. Furthermore, Repatha plays a vital role in lowering the incidence of major cardiovascular events such as myocardial infarction, stroke, and coronary revascularization. Amgen's comprehensive product lineup also encompasses Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. The company distributes its therapies worldwide, primarily serving healthcare providers, including physicians and their clinics, dialysis centers, hospitals, and pharmacies. Distribution is facilitated through pharmaceutical wholesale distributors, complemented by direct-to-consumer channels. Amgen actively engages in strategic collaborations. It has partnered with entities such as Novartis Pharma AG, UCB, Bayer HealthCare LLC, BeiGene, Ltd., Eli Lilly and Company, Datos Health, and Verastem, Inc., to jointly assess VS-6766 when combined with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. Another key alliance involves Kyowa Kirin Co., Ltd., for the co-development and commercialization of KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody targeting atopic dermatitis and other autoimmune conditions. Additionally, Amgen maintains research and development partnerships with Neumora Therapeutics, Inc. and Plexium, Inc.
🤖 AI Earnings Analysis
AMGN delivered a strong earnings beat—EPS surprise of 12.32% and revenue surprise of 6.67%—followed by a 6.23% one-week share gain.
AI-generated summary — powered by BigEarnings.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-04 | Q2 2026 | 5.62 | 6.29 | +12.32% | $10.05B | ✅ Beat | +4.57% | +6.23% | +14.21% |
| 2026-04-30 | Q1 2026 | 4.76 | 5.15 | +8.19% | $8.62B | ✅ Beat | -4.74% | -4.96% | -4.23% |
| 2026-02-03 | Q4 2025 | 4.75 | 5.29 | +11.37% | $9.87B | ✅ Beat | +8.16% | +7.70% | +9.32% |
| 2025-11-04 | Q3 2025 | 5.01 | 5.64 | +12.57% | $9.56B | ✅ Beat | +7.81% | +14.07% | +15.47% |
| 2025-08-05 | Q2 2025 | 5.27 | 6.02 | +14.23% | $9.18B | ✅ Beat | -5.13% | -5.03% | -5.90% |
| 2025-05-01 | Q1 2025 | 4.30 | 4.90 | +13.95% | $8.15B | ✅ Beat | -0.90% | -4.13% | +2.55% |
| 2025-02-04 | Q4 2024 | 5.08 | 5.31 | +4.53% | $9.09B | ✅ Beat | +6.50% | +2.64% | +10.85% |
| 2024-10-30 | Q3 2024 | 5.11 | 5.58 | +9.20% | $8.50B | ✅ Beat | +1.46% | +1.98% | -9.64% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $10.05B total
| Segment | Share | Revenue | YoY | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 |
|---|---|---|---|---|---|---|---|
| Other products | 16.9% | $1.70B | — | — | — | — | — |
| Repatha | 9.5% | $953.0M | — | — | — | — | — |
| Prolia | 7.5% | $759.0M | -32.4% | $1.04B | $1.17B | $1.10B | $1.12B |
| EVENITY | 7.1% | $714.0M | +37.8% | $399.0M | $431.0M | $442.0M | $518.0M |
| ENBREL | 5.8% | $580.0M | -4.0% | $825.0M | $1.01B | $510.0M | $604.0M |
| TEPEZZA | 5.7% | $576.0M | +14.1% | $488.0M | $460.0M | $381.0M | $505.0M |
| Other revenues | 5.1% | $517.0M | — | — | — | — | — |
By region
Q2 FY26 · $9.54B total
| Segment | Share | Revenue | YoY | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 |
|---|---|---|---|---|---|---|---|
| UNITED STATES | 73.3% | $6.99B | +10.5% | $5.98B | $7.07B | $5.66B | $6.32B |
| Non-US | 26.7% | $2.55B | +4.1% | $2.17B | $3.04B | $2.21B | $2.45B |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.